Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
The addition of palbociclib to maintenance anti-HER2 and endocrine therapies led to a significant improvement in progression-free survival over standard therapy, with increased toxic effects, mainly neutropenia. (Funded by Pfizer and others; PATINA ClinicalTrials.gov number, NCT02947685.).
Authors
- J Lanzillotti
- A DeMichele
- Carrie Strand (ORCID: https://orcid.org/0000-0001-7820-6138)
- F. Lynce
- Prudence A. Francis (ORCID: https://orcid.org/0000-0002-7207-9286)
- David Porter (ORCID: https://orcid.org/0000-0002-3115-8244)
- Otto Metzger
- J. Gligorov
- María Koehler (ORCID: https://orcid.org/0000-0002-4477-9621)
- Travis Dockter (ORCID: https://orcid.org/0000-0001-7315-8499)
- Pierre-Etienne Heudel (ORCID: https://orcid.org/0000-0002-8555-8921)
- L.A. Carey
- Santiago Escrivá-de-Romaní (ORCID: https://orcid.org/0000-0001-7816-7589)
- S. Goel
- Carter DuFrane
- E. Lim
- Ariadna Holynskyj
- Anna Wall
- Jennifer Spoenlein
- A. Prat
- Luca Gianni
- Prashanth Gopalakrishna
- Debu Tripathy
- Sibylle Loibl
- Sumithra Mandrekar
- Eva Ciruelos
- Kathy Miller
- Sagar Sardesai
- Ann H. Partridge
- Xavier Gonzàlez Farré
- Sherene Loi
- Suzette Delaloge
- Eric Gauthier
- Matthew Goetz
- Ines Vaz-Luis
- Cynthia Huang Bartlett
- Daniel G. Stover
- Eric P. Winer
Institutions
- Hebron University (PS)
- University of North Carolina Health Care (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Garvan Institute of Medical Research (AU)
- Inserm (FR)
- Pfizer (United States) (US)
- Alliance for Clinical Trials in Oncology (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Peter MacCallum Cancer Centre (AU)
- Institut Gustave Roussy (FR)
- Yale University (US)
- Sorbonne Université (FR)
- Research Institute Hospital 12 de Octubre (ES)
- Alliance Foundation Trials (US)
- Instituto Oncológico Dr. Rosell (ES)
- Assistance Publique – Hôpitaux de Paris (FR)
- Fondazione Michelangelo (IT)
- Vall d'Hebron Institut de Recerca (ES)
- Centre Léon Bérard (FR)
- Auckland District Health Board (NZ)
- Dana-Farber Cancer Institute (US)
- Cancer Clinic (US)
- Vall d'Hebron Hospital Universitari (ES)
- German Breast group (DE)
- UniCancer Group (FR)
- Kliniken Essen-Mitte (DE)
- Hôpital Tenon (FR)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2026-01-28
- DOI
- https://doi.org/10.1056/nejmoa2511218
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 36.44